124 related articles for article (PubMed ID: 24720539)
21. Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation.
Teo JL; Ma H; Nguyen C; Lam C; Kahn M
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12171-6. PubMed ID: 16093313
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.
Nagao R; Ashihara E; Kimura S; Strovel JW; Yao H; Takeuchi M; Tanaka R; Hayashi Y; Hirai H; Padia J; Strand K; Maekawa T
Cancer Lett; 2011 Dec; 312(1):91-100. PubMed ID: 21906872
[TBL] [Abstract][Full Text] [Related]
23. β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells.
Yu W; Li L; Zheng F; Yang W; Zhao S; Tian C; Yin W; Chen Y; Guo W; Zou L; Deng W
Cell Physiol Biochem; 2017; 44(2):467-478. PubMed ID: 29141249
[TBL] [Abstract][Full Text] [Related]
24. Taking the road less traveled - the therapeutic potential of CBP/β-catenin antagonists.
Kahn M
Expert Opin Ther Targets; 2021 Sep; 25(9):701-719. PubMed ID: 34633266
[TBL] [Abstract][Full Text] [Related]
25. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
He K; Xu T; Xu Y; Ring A; Kahn M; Goldkorn A
Int J Cancer; 2014 Jan; 134(1):43-54. PubMed ID: 23784558
[TBL] [Abstract][Full Text] [Related]
26. Amide-linked local anesthetics preferentially target leukemia stem cell through inhibition of Wnt/β-catenin.
Ni J; Xie T; Xiao M; Xiang W; Wang L
Biochem Biophys Res Commun; 2018 Sep; 503(2):956-962. PubMed ID: 29932919
[TBL] [Abstract][Full Text] [Related]
27. Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators.
Kahn M
Prog Mol Biol Transl Sci; 2018 Jan; 153():209-244. PubMed ID: 29389517
[TBL] [Abstract][Full Text] [Related]
28. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
29. CBP/p300 are bimodal regulators of Wnt signaling.
Li J; Sutter C; Parker DS; Blauwkamp T; Fang M; Cadigan KM
EMBO J; 2007 May; 26(9):2284-94. PubMed ID: 17410209
[TBL] [Abstract][Full Text] [Related]
30. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
[TBL] [Abstract][Full Text] [Related]
31. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
32. WNT/β-catenin signaling inhibits CBP-mediated RelA acetylation and expression of proinflammatory NF-κB target genes.
Ma B; Fey M; Hottiger MO
J Cell Sci; 2015 Jul; 128(14):2430-6. PubMed ID: 26021349
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer.
Zhang Q; Lou Y; Zhang J; Fu Q; Wei T; Sun X; Chen Q; Yang J; Bai X; Liang T
Mol Cancer; 2017 Jul; 16(1):119. PubMed ID: 28705232
[TBL] [Abstract][Full Text] [Related]
35. Altering cancer transcriptomes using epigenomic inhibitors.
Gaddis M; Gerrard D; Frietze S; Farnham PJ
Epigenetics Chromatin; 2015; 8():9. PubMed ID: 26191083
[TBL] [Abstract][Full Text] [Related]
36. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
[TBL] [Abstract][Full Text] [Related]
37. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
[TBL] [Abstract][Full Text] [Related]
38. Functional analysis of novel phosphorylation sites of CREB-binding protein using mass spectrometry and mammalian two-hybrid assays.
Xia Z; Guo M; Ma H
Proteomics; 2011 Sep; 11(17):3444-51. PubMed ID: 21751375
[TBL] [Abstract][Full Text] [Related]
39. HIF-α Promotes Chronic Myelogenous Leukemia Cell Proliferation by Upregulating p21 Expression.
Chen H; Shen Y; Gong F; Jiang Y; Zhang R
Cell Biochem Biophys; 2015 May; 72(1):179-83. PubMed ID: 25596666
[TBL] [Abstract][Full Text] [Related]
40. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
